logo ecco

logo ecco

Portal
  • About ECCO
    • General Assembly
    • Governing Board
    • Committees / Operational Board
    • The Council of National Representatives
    • Solidarity for Ukraine
    • Elections
    • Community Videos
    • Affiliate Societies & Partners
    • Y-ECCO Contributors
    • ECCO Office
    • ECCO Disclosures
    • ECCO Code of Conduct
    • REACH
    • Diversity, Equity & Inclusion
  • Congresses & Events
    • Upcoming
      • 21st Congress of ECCO 2026 - Stockholm
    • Past
      • 20th Congress of ECCO 2025 - Berlin
      • 19th Congress of ECCO 2024 - Stockholm
    • Event Calendar
    • Congress Statistics
    • Quality Assurance/Endorsement
  • Membership
    • Individual Membership
    • Country Members
    • Corporate Membership
    • Affiliate ECCO Societies
  • Education
    • E-QUALITY
    • e-Learning
    • Letters from the e-Learning Editor-in-Chief
    • Educational Workshops
    • Congress Educational Programme
    • IBD Nurse Education Programme
    • Y-ECCO Mentorship Forum
    • Fast Facts in IBD
  • Science
    • UR-CARE
    • The Reviewers of ECCO
    • The Reviewers of 2024
    • Fellowships, Grants & Awards
    • ECCO Young Researcher Award
    • Scientific Workshops
    • Research Projects
    • ECCO CONFER Cases
  • Publications
    • JCC
    • JCC Plus
    • JCC on X/Twitter
    • Guidelines
    • Topical Review
    • Position Statements
    • Scientific Workshop Papers
    • ECCO News
    • ECCO IBD App
    • Congress Abstracts
    • Surveys
    • Other publications
    • eNewsletter

ECCO'25 Abstracts

ECCO'25 Abstracts on the JCC Website

ECCO'25 Abstract Book PDF Version

ECCO'25 Abstracts COI Disclosure

ECCO'24 Abstracts

ECCO'24 Abstracts on the JCC Website

ECCO'24 Abstract Book PDF Version

ECCO'24 Abstracts COI Disclosure

Poster Presentations: Clinical: Diagnosis and Outcome 2023

P147 Trends in choice of first line biologic therapy for patients with Inflammatory Bowel Disease. An observational cohort study.

Fernando, S.(1)*;Abu-Rgeef, R.(1);Menon, S.(1);So, K.(1);Venugopal, K.(1);Picardo, S.(1);

(1)Royal Perth Hospital, Department of Gastroenterology and Hepatology, Perth, Australia;

Background

Biologic therapies have revolutionised the management of Inflammatory Bowel Disease (IBD) with increasing utilisation over the last decade. The anti-Tumour Necrosis Factor-alpha (anti-TNF) agents (Infliximab (IFX) and Adalimumab (ADA)) as well as newer agents (Ustekinumab (UST) and Vedolizumab (VED)) all have well demonstrated safety and efficacy profiles in the management of IBD. The choice of an optimal first line biologic remains unclear due to lack of comparative randomised trials and real-world studies; however, certain patient and disease characteristics may influence this choice. The aims of this study were to explore temporal trends in choice of 1st-line biologic therapy and factors that influence this choice.

Methods

A retrospective observational cohort study of all patients with IBD that commenced induction and completed at least one maintenance dose of a biologic therapy between 1st January 2015 and 31st December 2021. Relevant patient and disease-specific factors were collected, including patient comorbidities (ischaemic heart disease, malignancy and opportunistic infections) at time of diagnosis, for each eligible patient. Factors affecting choice of biologic therapy were compared using ANOVA and c2 test.

Results

280 patients were included, with 50.7% being male and median age of IBD diagnosis of 29 years. There was a progressive increase in biologic use over time, with 15 patients commencing1st biologic therapy in 2015, rising to 58 patients in 2021. UST has overtaken IFX and ADA as first line choice for Crohn’s disease (CD) since its introduction in 2018 (Figure 1). IFX has remained preferred first line therapy for ulcerative colitis (UC) over VED and ADA, with stable trend in choice over time. Factors with significant differences in choice of first line biologic therapy included age (UST for older age of commencement), IBD subtype (higher proportion of patients commencing ADA had CD, whereas higher proportion of patients commencing VED had UC), disease location (VED was preferred for colonic over ileal CD), and malignancy (UST was preferred) (Table 1).

Conclusion

- There has been a steady rise in the number of patients commencing biologic therapies, with an average increase of 24% per year from 2015 to 2021.
- Ustekinumab has replaced anti-TNF therapy as the preferred first line biologic for Crohn’s disease; a trend likely secondary to the comparatively favourable safety profile of ustekinumab. Ustekinumab was preferred in older patients and those with history of malignancy.
- Infliximab remains the preferred first line therapy for ulcerative colitis with stable trends in choice.
- The presence of perianal disease was not a significant factor affecting choice.

  • Posted in: Poster Presentations: Clinical: Diagnosis and Outcome 2023
Logo_contact.png     T: +43 (0)1 710 22 42-0
F: +43 (0)1 710 22 42-001
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Home
  • Sitemap
  • Contact
  • Imprint
  • Data privacy statement
  • Media Policy

  • About ECCO
    • General Assembly
    • Governing Board
    • Committees / Operational Board
    • The Council of National Representatives
    • Solidarity for Ukraine
    • Elections
    • Community Videos
    • Affiliate Societies & Partners
    • Y-ECCO Contributors
    • ECCO Office
    • ECCO Disclosures
    • ECCO Code of Conduct
    • REACH
    • Diversity, Equity & Inclusion
  • Congresses & Events
    • Upcoming
      • 21st Congress of ECCO 2026 - Stockholm
    • Past
      • 20th Congress of ECCO 2025 - Berlin
      • 19th Congress of ECCO 2024 - Stockholm
    • Event Calendar
    • Congress Statistics
    • Quality Assurance/Endorsement
  • Membership
    • Individual Membership
    • Country Members
    • Corporate Membership
    • Affiliate ECCO Societies
  • Education
    • E-QUALITY
    • e-Learning
    • Letters from the e-Learning Editor-in-Chief
    • Educational Workshops
    • Congress Educational Programme
    • IBD Nurse Education Programme
    • Y-ECCO Mentorship Forum
    • Fast Facts in IBD
  • Science
    • UR-CARE
    • The Reviewers of ECCO
    • The Reviewers of 2024
    • Fellowships, Grants & Awards
    • ECCO Young Researcher Award
    • Scientific Workshops
    • Research Projects
    • ECCO CONFER Cases
  • Publications
    • JCC
    • JCC Plus
    • JCC on X/Twitter
    • Guidelines
    • Topical Review
    • Position Statements
    • Scientific Workshop Papers
    • ECCO News
    • ECCO IBD App
    • Congress Abstracts
    • Surveys
    • Other publications
    • eNewsletter